Presentation and progression of MPO-ANCA interstitial lung disease

[1]  C. Pagnoux,et al.  Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis: an update on pathogenesis and treatment , 2023, Current opinion in pulmonary medicine.

[2]  U. Specks,et al.  Proteomic profile of uninvolved versus crescentic glomeruli in MPO-ANCA-associated vasculitis , 2023, Clinical Kidney Journal.

[3]  H. Anders,et al.  Glomerulonephritis: immunopathogenesis and immunotherapy , 2023, Nature Reviews Immunology.

[4]  K. Kuwano,et al.  Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review , 2022, Journal of clinical medicine.

[5]  F. Martinez,et al.  Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2022, American journal of respiratory and critical care medicine.

[6]  P. Merkel,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis , 2022, Annals of the Rheumatic Diseases.

[7]  U. Specks,et al.  Maintenance of Remission and Risk of Relapse in Myeloperoxidase-Positive ANCA-Associated Vasculitis with Kidney Involvement , 2022, Clinical journal of the American Society of Nephrology : CJASN.

[8]  M. Bando,et al.  MPO-ANCA positive interstitial pneumonia: Current knowledge and future perspectives , 2021, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[9]  G. Raghu,et al.  Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review , 2021, European Respiratory Review.

[10]  Yusuke Okabayashi,et al.  Long-Term Renal Survival in Antineutrophil Cytoplasmic Antibody–Associated Glomerulonephritis With Complement C3 Deposition , 2021, Kidney international reports.

[11]  J. Fisher,et al.  Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease , 2021, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[12]  J. Alexandre,et al.  POS0118 A WORLDWIDE PHARMACOEPIDEMIOLOGICAL UPDATE OF DRUG-ASSOCIATED ANCA-ASSOCIATED VASCULITIS AT THE TIME OF TARGETED THERAPIES , 2021 .

[13]  E. Bargagli,et al.  Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association , 2021, Journal of clinical medicine.

[14]  M. Takemura,et al.  Interstitial lung disease with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis in elderly patients , 2021, Rheumatology International.

[15]  P. Merkel,et al.  Pulmonary Involvement in Primary Systemic Vasculitides. , 2021, Rheumatology.

[16]  X. Ao,et al.  Glomerular Immune Deposition in MPO-ANCA Associated Glomerulonephritis Is Associated With Poor Renal Survival , 2021, Frontiers in Immunology.

[17]  Mengtao Li,et al.  Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody , 2021, BMC Pulmonary Medicine.

[18]  P. Merkel,et al.  Avacopan for the Treatment of ANCA-Associated Vasculitis. , 2021, The New England journal of medicine.

[19]  K. Hata,et al.  Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease , 2021, Scientific Reports.

[20]  P. Parronchi,et al.  Spectrum of Fibrotic Lung Diseases. , 2020, The New England journal of medicine.

[21]  T. Mustelin,et al.  Role of Neutrophils in Systemic Vasculitides , 2020, Frontiers in Immunology.

[22]  Guangfa Wang,et al.  Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: A systematic literature review and meta-analysis , 2020, Chronic respiratory disease.

[23]  A. Vaglio,et al.  Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome , 2020, Clinical kidney journal.

[24]  V. Cottin,et al.  Spectrum of Fibrotic Lung Diseases. , 2020, The New England journal of medicine.

[25]  P. Merkel,et al.  ANCA-associated vasculitis , 2020, Nature Reviews Disease Primers.

[26]  S. Vermeire,et al.  2020 international consensus on ANCA testing beyond systemic vasculitis. , 2020, Autoimmunity reviews.

[27]  D. Cornec,et al.  Lung involvement in ANCA-associated vasculitis. , 2020, Presse medicale.

[28]  Dante S. Bortone,et al.  Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis. , 2020, Journal of autoimmunity.

[29]  William J. Astle,et al.  Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status , 2019, Nature Communications.

[30]  H. Collard,et al.  Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients with Idiopathic Pulmonary Fibrosis. , 2019, Chest.

[31]  Chih-Wei Yang,et al.  High anti-neutrophil cytoplasmic antibody titers are associated with the requirement of permanent dialysis in patients with myeloperoxidase-ANCA-associated vasculitis. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[32]  D. Cornec,et al.  Lung Involvement in ANCA-Associated Vasculitis , 2019, Rare Diseases of the Immune System.

[33]  L. Flores-Suárez,et al.  Interstitial Lung Disease and ANCA-Associated Vasculitis , 2019, Current Treatment Options in Rheumatology.

[34]  A. Ishizu,et al.  Formation and Disordered Degradation of Neutrophil Extracellular Traps in Necrotizing Lesions of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. , 2019, The American journal of pathology.

[35]  Takeshi Johkoh,et al.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.

[36]  N. Inui,et al.  Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias , 2018, PloS one.

[37]  S. Loosen,et al.  C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis. , 2017, Kidney international.

[38]  J. Thurman,et al.  Review: The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases , 2017, Arthritis & rheumatology.

[39]  C. Kallenberg,et al.  Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis , 2017 .

[40]  M. Jadoul,et al.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. , 2017, Journal of the American Society of Nephrology : JASN.

[41]  P. van Paassen,et al.  Complement in ANCA-associated glomerulonephritis , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  M. Alba,et al.  Interstital lung disease in ANCA vasculitis. , 2017, Autoimmunity reviews.

[43]  V. Tesar,et al.  Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts , 2017, RMD Open.

[44]  T. Schall,et al.  Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study , 2016, PloS one.

[45]  G. Fernández-Juárez,et al.  Glomerular C3d as a novel prognostic marker for renal vasculitis. , 2016, Human pathology.

[46]  D. Cornec,et al.  ANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients , 2016, Nature Reviews Rheumatology.

[47]  T. Baba,et al.  Clinical features of usual interstitial pneumonia with anti‐neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis , 2016, Respirology.

[48]  N. Yoshikawa,et al.  Myeloperoxidase anti‐neutrophil cytoplasmic antibody affinity is associated with the formation of neutrophil extracellular traps in the kidney and vasculitis activity in myeloperoxidase anti‐neutrophil cytoplasmic antibody‐associated microscopic polyangiitis , 2016, Nephrology.

[49]  Rohit Sharma.  Revised International Chapel Hill Consensus Conference nomenclature of vasculitides , 2016, Radiopaedia.org.

[50]  Jai Radhakrishnan,et al.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. , 2016, Journal of the American Society of Nephrology : JASN.

[51]  I. Brochériou,et al.  Idiopathic lung fibrosis and anti myeloperoxidase glomerulonephritis: the tree that hides the forest , 2015, BMC Pulmonary Medicine.

[52]  F. Caputo,et al.  Microscopic polyangiitis associated with pulmonary fibrosis , 2015, Clinical Rheumatology.

[53]  H. Yamanaka,et al.  Interstitial Lung Disease with ANCA-associated Vasculitis , 2015, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.

[54]  P. Grenier,et al.  Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis , 2014, Medicine.

[55]  Kaifeng Xu,et al.  A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China , 2014, BMC Pulmonary Medicine.

[56]  L. Mouthon,et al.  Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? , 2013, Annals of the rheumatic diseases.

[57]  Min Chen,et al.  Epitope Analysis of Anti-Myeloperoxidase Antibodies in Patients with ANCA-Associated Vasculitis , 2013, PloS one.

[58]  E. Miyazaki,et al.  Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. , 2013, Respiratory medicine.

[59]  P. Heeringa,et al.  Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. , 2013, The Journal of clinical investigation.

[60]  P. Ind,et al.  Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. , 2011, Rheumatology.

[61]  J. James,et al.  Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes , 2011, Clinical and experimental immunology.

[62]  M. Hickey,et al.  Antimyeloperoxidase antibodies rapidly induce alpha-4-integrin-dependent glomerular neutrophil adhesion. , 2009, Blood.

[63]  F. Luft,et al.  C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.

[64]  Min Chen,et al.  Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[65]  Z. Amoura,et al.  Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature , 2008, Annals of the rheumatic diseases.

[66]  V. Cottin,et al.  ANCA-associated lung fibrosis: analysis of 17 patients. , 2008, Respiratory medicine.

[67]  R. Dhôte,et al.  [Churg-Strauss syndrome and pulmonary fibrosis: an unusual association]. , 2006, Presse medicale.

[68]  L. Mouthon,et al.  Microscopic polyangiitis and polyarteritis nodosa: how and when do they start? , 2003, Arthritis and rheumatism.

[69]  C. Kallenberg,et al.  Antimyeloperoxidase-associated lung disease. An experimental model. , 1999, American journal of respiratory and critical care medicine.

[70]  C. Kallenberg,et al.  Systemic injection of products of activated neutrophils and H2O2 in myeloperoxidase-immunized rats leads to necrotizing vasculitis in the lungs and gut. , 1997, The American journal of pathology.

[71]  C. Kallenberg,et al.  Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. , 1996, The American journal of pathology.

[72]  J. Ryu,et al.  Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. , 1990, Mayo Clinic proceedings.

[73]  T. Colby,et al.  Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: a retrospective analysis. , 2020, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[74]  B. Bonnotte,et al.  Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. , 2019, Journal of autoimmunity.

[75]  P. Kurtin,et al.  Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[76]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[77]  Sharon A Chung,et al.  Microscopic polyangiitis. , 2010, Rheumatic diseases clinics of North America.

[78]  M. Bissell.  Alternative Complement Pathway in the Pathogenesis of Disease Mediated by Anti-Neutrophil Cytoplasmic Autoantibodies , 2009 .